IMMUNOHISTOCHEMISTRY, CD 7

The IHC – CD7 (Cluster of Differentiation 7) test is an immunohistochemistry-based diagnostic assay used to detect CD7 protein expression in tissue samples. CD7 is a transmembrane glycoprotein found primarily on T-lymphocytes and natural killer (NK) cells, making it an important marker for identifying T-cell lineage and evaluating lymphoid malignancies.

This test is widely used in hematopathology and oncology to diagnose and classify T-cell lymphomas, T-cell leukemias, and other lymphoproliferative disorders. CD7 expression patterns can help pathologists distinguish normal immune cells from abnormal malignant cell populations and support accurate immunophenotyping.

Benefits of the Test

• Helps identify T-cell lineage in tissue samples
• Assists in diagnosing T-cell lymphomas and leukemias
• Supports classification of lymphoid malignancies
• Improves diagnostic accuracy in hematological disorders
• Helps guide treatment planning and prognosis evaluation

Why Doctors Recommend This Test

Doctors recommend the IHC CD7 test when there is suspicion of T-cell neoplasms or lymphoid malignancies. It is commonly used in:

• Diagnosis of peripheral T-cell lymphoma
• Evaluation of T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
• Assessment of cutaneous T-cell lymphoma
• Investigation of lymph node enlargement
• Comprehensive immunophenotyping of lymphoid tumors

CD7 is often used together with markers such as CD3, CD4, CD5, CD8, CD56, and Ki-67 to provide a detailed profile of lymphoid cells and support precise diagnosis.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy, bone marrow, or surgical tissue sample
• No fasting or medication restrictions are needed
• Clinical history and previous pathology findings may aid interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen type and laboratory workflow.

Who Should Take This Test

• Patients with suspected T-cell lymphoma
• Individuals with suspected T-cell leukemia
• Cases of unexplained lymph node enlargement
• Patients undergoing bone marrow evaluation
• Oncology patients requiring lymphoid tumor classification

The IHC CD7 test is an important diagnostic tool in hematopathology. By identifying T-cell and NK-cell lineage markers, it helps clinicians accurately diagnose lymphoid malignancies and develop appropriate treatment strategies.